|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lissoni AA, Colombo N, Pellegrino A, Parma
G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, et
al: A phase II, randomized trial of neo-adjuvant chemotherapy
comparing a three-drug combination of paclitaxel, ifosfamide and
cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by
radical surgery in patients with locally advanced squamous cell
cervical carcinoma: The snap-02 Italian collaborative study. Ann
Oncol. 20:660–665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katanyoo K, Tangjitgamol S, Chongthanakorn
M, Tantivatana T, Manusirivithaya S, Rongsriyam K and Cholpaisal A:
Treatment outcomes of concurrent weekly carboplatin with radiation
therapy in locally advanced cervical cancer patients. Gynecol
Oncol. 123:571–576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Symonds RP, Gourley C, Davidson S, Carty
K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M,
et al: Cediranib combined with carboplatin and paclitaxel in
patients with metastatic or recurrent cervical cancer (CIRCCa): A
randomised, double-blind, placebo-controlled phase 2 trial. Lancet
Oncol. 16:1515–1524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Monk BJ and Tewari KS: Evidence-based
therapy for recurrent cervical cancer. J Clin Oncol. 32:2687–2690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE,
Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of
four cisplatin-containing doublet combinations in stage IVB,
recurrent, or persistent cervical carcinoma: A Gynecologic Oncology
Group Study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tillmann H and Eschrich K: Isolation and
characterization of an allelic cDNA for human muscle
fructose-1,6-bisphosphatase. Gene. 212:295–304. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Wang X, Zhang J, Lam EK, Shin VY,
Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC: Warburg effect
revisited: An epigenetic link between glycolysis and gastric
carcinogenesis. Oncogene. 29:442–450. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen M, Zhang J, Li N, Qian Z, Zhu M, Li
Q, Zheng J, Wang X and Shi G: Promoter hypermethylation mediated
downregulation of FBP1 in human hepatocellular carcinoma and colon
cancer. PLoS One. 6:e255642011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li B, Qiu B, Lee DS, Walton ZE, Ochocki
JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC:
Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bigl M, Jandrig B, Horn LC and Eschrich K:
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase
genes in cancer. Biochem Biophys Res Commun. 377:720–724. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heiden MG Vander, Cantley LC and Thompson
CB: Understanding the warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeBerardinis RJ and Thompson CB: Cellular
metabolism and disease: What do metabolic outliers teach us? Cell.
148:1132–1144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng X, Cai SM, Li ZT, Wu XH, Ding YQ,
Wang XE and Zang RY: Concurrent chemotherapy and adjuvant extended
field irradiation after radical surgery for cervical cancer
patients with lymph node metastases. Int J Gynecol Cancer.
18:779–784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi TY, Yang G, Tu XY, Yang JM, Qian J, Wu
XH, Zhou XY, Cheng X and Wei Q: RAD52 variants predict platinum
resistance and prognosis of cervical cancer. PLoS One.
7:e504612012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng X, Yang G, Schmeler KM, Coleman RL,
Tu X, Liu J and Kavanagh JJ: Recurrence patterns and prognosis of
endometrial stromal sarcoma and the potential of tyrosine
kinase-inhibiting therapy. Gynecol Oncol. 121:323–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaupel P, Kallinowski F and Okunieff P:
Blood flow, oxygen and nutrient supply, and metabolic
microenvironment of human tumors: A review. Cancer Res.
49:6449–6465. 1989.PubMed/NCBI
|
|
18
|
Fella K, Glückmann M, Hellmann J, Karas M,
Kramer PJ and Kröger M: Use of two-dimensional gel electrophoresis
in predictive toxicology: Identification of potential early protein
biomarkers in chemically induced hepatocarcinogenesis. Proteomics.
5:1914–1927. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hirata H, Sugimachi K, Komatsu H, Ueda M,
Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, et al:
Decreased expression of fructose-1,6-bisphosphatase associates with
glucose metabolism and tumor progression in hepatocellular
carcinoma. Cancer Res. 76:3265–3276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
22
|
Dong C, Yuan T, Wu Y, Wang Y, Fan TW,
Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al: Loss of FBP1 by
snail-mediated repression provides metabolic advantages in
basal-like breast cancer. Cancer Cell. 23:316–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Green JA, Kirwan JM, Tierney JF, Symonds
P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence
after concomitant chemotherapy and radiotherapy for cancer of the
uterine cervix: A systematic review and meta-analysis. Lancet.
358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zuliani AC, Esteves SC, Teixeira LC,
Teixeira JC, de Souza GA and Sarian LO: Concomitant cisplatin plus
radiotherapy and high-dose-rate brachytherapy versus radiotherapy
alone for stage IIIB epidermoid cervical cancer: A randomized
controlled trial. J Clin Oncol. 32:542–547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kitagawa R, Katsumata N, Shibata T, Kamura
T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M,
Satoh T and Yoshikawa H: Paclitaxel plus carboplatin versus
paclitaxel plus cisplatin in metastatic or recurrent cervical
cancer: The open-label randomized phase III trial JCOG0505. J Clin
Oncol. 33:2129–2135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mabuchi S, Isohashi F, Yokoi T, Takemura
M, Yoshino K, Shiki Y, Ito K, Enomoto T, Ogawa K and Kimura T: A
phase II study of postoperative concurrent carboplatin and
paclitaxel combined with intensity-modulated pelvic radiotherapy
followed by consolidation chemotherapy in surgically treated
cervical cancer patients with positive pelvic lymph nodes. Gynecol
Oncol. 141:240–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dunst J and Haensgen G: Simultaneous
radiochemotherapy in cervical cancer: Recommendations for
chemotherapy. Strahlenther Onkol. 177:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sowa T, Menju T, Chen-Yoshikawa TF,
Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H,
Hijiya K, Aoyama A, et al: Hypoxia-inducible factor 1 promotes
chemoresistance of lung cancer by inducing carbonic anhydrase IX
expression. Cancer Med. 6:288–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song K, Li M, Xu X, Xuan Li, Huang G and
Liu Q: Resistance to chemotherapy is associated with altered
glucose metabolism in acute myeloid leukemia. Oncol Lett.
12:334–342. 2016.PubMed/NCBI
|
